• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
Market Cap | 20.309 Billion | Shares Outstanding | 231.157 Million | Avg 30-day Volume | 4.7 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.74 |
Price to Revenue | 402.1664 | Debt to Equity | 0.0 | EBITDA | -308.786 Million |
Price to Book Value | 13.8066 | Operating Margin | -1536.6586 | Enterprise Value | 7.215 Billion |
Current Ratio | 12.841 | EPS Growth | -0.042 | Quick Ratio | 12.279 |
1 Yr BETA | 1.878 | 52-week High/Low | 0.0 / | Profit Margin | -1735.6669 |
Operating Cash Flow Growth | -88.5418 | Altman Z-Score | 8.3575 | Free Cash Flow to Firm | -146.819 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
ITRI LORETTTA M CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2020-10-23 | 0 |
|
No longer subject to file | 2020-10-23 | 0 | |
|
No longer subject to file | 2020-10-23 | 0 | |
|
No longer subject to file | 2020-10-23 | 0 | |
|
No longer subject to file | 2020-10-23 | 0 | |
|
No longer subject to file | 2020-10-23 | 0 | |
ANDREWS KURT J. CHIEF HUMAN RESOURCES OFFICER |
|
No longer subject to file | 2020-10-23 | 0 |
|
No longer subject to file | 2020-10-23 | 0 | |
|
No longer subject to file | 2020-10-23 | 0 | |
DELANEY BRENDAN CHIEF COMMERCIAL OFFICER |
|
No longer subject to file | 2020-10-23 | 0 |
MALIK USAMA CHIEF FIN. & BUSINESS OFFICER |
|
No longer subject to file | 2020-10-23 | 0 |
FRICKER WILLIAM PRINCIPAL ACCOUNTING OFFICER |
|
No longer subject to file | 2020-10-23 | 0 |
FREEDBERG JARED GEN. COUNSEL & CORP. SECRETARY |
|
No longer subject to file | 2020-10-23 | 0 |
BALL BRYAN CHIEF QUALITY OFFICER |
|
No longer subject to file | 2020-10-23 | 0 |
SEMERJIAN HAROUT PRESIDENT AND CEO |
|
50,075 | 2020-04-16 | 0 |
ROSENBERG MORRIS CHIEF TECHNOLOGY OFFICER |
|
0 | 2019-09-06 | 0 |
IANNONE ROBERT CHIEF MEDICAL OFFICER |
|
0 | 2019-03-14 | 0 |
PEHL MICHAEL F. PRESIDENT AND CEO |
|
0 | 2018-09-14 | 0 |
|
7,387,537 | 2018-02-28 | 0 | |
|
90,788 | 2017-11-20 | 0 | |
|
16,064,461 | 2017-11-14 | 0 | |
|
16,064,461 | 2017-11-14 | 0 | |
|
5,906,233 | 2017-08-31 | 0 | |
GARONE MICHAEL CHIEF FINANCIAL OFFICER |
|
0 | 2017-07-03 | 0 |
|
No longer subject to file | 2017-06-30 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
0 | 2017-01-08 | 0 | |
|
78,325 | 2016-12-02 | 0 | |
|
0 | 2015-12-02 | 0 | |
|
No longer subject to file | 2015-12-01 | 0 | |
PFREUNDSCHUH PETER P. CHIEF FINANCIAL OFFICER |
|
29,706 | 2015-08-20 | 0 |
|
No longer subject to file | 2013-12-04 | 0 | |
|
No longer subject to file | 2013-12-04 | 0 | |
GORMAN GERARD G SVP, FIN. , AND CFO |
|
0 | 2013-08-16 | 0 |
|
9,167 | 2011-12-07 | 0 | |
|
6,667 | 2009-12-02 | 0 | |
JAFFE MARVIN |
|
15,000 | 2006-08-24 | 0 |
|
25,000 | 2006-08-24 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
American Century Quantitative Equity Funds, Inc.- AC Alternatives Equity Market Neutral Fund | IMMU | -4999.0 shares, $-105778.84 | 2019-12-31 | N-PORT |
American Century Quantitative Equity Funds, Inc.- AC Alternatives Disciplined Long Short Fund | IMMU | -4122.0 shares, $-87221.52 | 2019-12-31 | N-PORT |
American Century Quantitative Equity Funds, Inc.- Core Equity Plus Fund | IMMU | -27324.0 shares, $-362316.24 | 2019-09-30 | N-PORT |
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund | IMMU | -73.0 shares, $-6207.19 | 2020-09-30 | N-PORT |
American Century Quantitative Equity Funds, Inc.- NT Core Equity Plus Fund | IMMU | -83315.0 shares, $-1104756.9 | 2019-09-30 | N-PORT |
Trust for Professional Managers- Convergence Market Neutral Fund | IMMU | -1592.0 shares, $-70939.52 | 2020-08-31 | N-PORT |
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund | IMMU | -50.0 shares, $-663.0 | 2019-09-30 | N-PORT |